Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Overlap syndromes.

Ulrich Beuers1, Christian Rust

  • 1Department of Medicine II-Grosshadern, Ludwig Maximilians-University of Munich, Germany. Beuers@med.uni-muenchen.de

Seminars in Liver Disease
|September 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation.

Alimentary pharmacology & therapeutics·2026
Same author

Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Reply to 'The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view'.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Children's experience of screening and evaluation for MASLD in overweight and obesity.

Obesity research & clinical practice·2025
Same author

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study.

The American journal of gastroenterology·2025
Same author

PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study.

JHEP reports : innovation in hepatology·2025
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Overlap syndromes combine features of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Early treatment with ursodeoxycholic acid and immunosuppressants is crucial to prevent liver failure.

Area of Science:

  • Hepatology
  • Autoimmune Liver Diseases

Background:

  • Overlap syndromes represent complex variants of major autoimmune hepatobiliary diseases: autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).
  • These syndromes are characterized by a combination of hepatitic and cholestatic features, often leading to progressive liver disease, cirrhosis, and liver failure if untreated.

Observation:

  • AIH-PBC overlap affects nearly 10% of adults with AIH or PBC.
  • AIH-PSC overlap is observed in 6-8% of pediatric and young adult patients with AIH or PSC.
  • Case reports document transitions between AIH, PBC, and PSC, including overlap with autoimmune cholangitis.

Findings:

  • Patients present with mixed biochemical and histological signs of the involved autoimmune liver diseases.
  • The prevalence varies, with AIH-PBC overlap being more common in adults and AIH-PSC in younger populations.

Related Experiment Videos

  • Disease progression is typical without appropriate intervention.

    • Implications:

    • Early diagnosis and combined therapy are essential for managing autoimmune liver disease overlap syndromes.
    • Treatment involves ursodeoxycholic acid for cholestasis and corticosteroids/azathioprine for immunosuppression.
    • Liver transplantation remains the definitive treatment for end-stage liver disease resulting from these conditions.